GLP-1 weight loss drugs are changing how people eat out, pushing diners toward smaller orders and cheaper restaurant meals.

Real-world data on the use of GLP-1 drugs such as Wegovy suggest that some patients can maintain weight loss 6 months after ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

With more Black women over 40 using GLP-1s, we break down the risks when it comes to micro-dosing the drug for menopausal weight gain.

U.S. airlines stand to reap the benefits as more passengers slim down thanks to the popularity of GLP-1 weight-loss drugs.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.

AbbVie Inc. (NYSE: ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in.

Research is suggesting that consuming substances like ketamine and MDMA could make it easier to make lifestyle changes, but ...

Patients who stop taking popular injectable weight-loss medications typically regain much of the weight they lost within two ...